888-633-5850

AstraZeneca’s researchers are now trying to provide rejected drugs and molecules with a second life. Instead of throwing them out after rejection, they search for their untapped potential.

This 9-person research team focuses on that fact that many successes come from past failures. What might not work for one disease could help with the development to combat another. And there is no sense wasting shelved drugs where they could be used to advance drug-related research.

In a recent article published by The Wall Street Journal, Denise Roland writes:

“AstraZeneca is aiming to build credibility with academic scientists as part of a broader move to drastically improve its research-and-development output, which until just a few years ago was among the industry’s worst. It hopes that making its unwanted molecules readily available to university researchers will give it an edge over its rivals, most of which are reluctant to dedicate resources to rejected drugs.”

The development of drugs in the United States is a major part of the increase in longevity around the world. Reusing data from past failures for future compounds in other areas is a great concept. Hopefully, this will transition to cost savings for companies and consumers of future products.

Read AstraZeneca Gives Rejected Drugs a Second Life, from The Wall Street Journal for more information.